Patients, Doctors Await FDA Decision on Experimental Alzheimer’s Drug
THURSDAY, Jan. 5, 2023 (HealthDay News) — Lecanemab: It’s an experimental medication that’s been shown in trials to slow cognitive decline in people with Alzheimer’s disease. It’s also up for accelerated approval by the U.S. Food and Drug Administration, with a decision expected by Jan. 6. However, the drug hasContinue Reading